Rachel Leheny is the founder of CalciMedica. CalciMedica has raised $15M in total funding. Latest round: Series C. Based in La Jolla, Calif., United States.
Rachel Leheny, Ph.D., is the Chief Executive Officer of CalciMedica, a clinical-stage biotechnology company focused on developing novel therapies based on CRAC channel inhibition. The company secured a $15 million Series C financing round in May 2020. This funding was intended to advance ongoing clinical trials for their lead drug candidate, Auxora, particularly in patients with COVID-19 pneumonia, and to support its commercial manufacturing.
Full founder directory · Investor directory · Company funding database · Fundraising library